Logan R A, O'Brien T J, Greaves M W
Clin Exp Dermatol. 1989 Jan;14(1):25-8. doi: 10.1111/j.1365-2230.1989.tb00877.x.
A controlled trial of 4-weeks oral photochemotherapy (PUVA) on 14 patients with severe symptomatic dermatographism produced a clinically useful reduction in itching in five patients. In four of these patients itching had relapsed to pre-treatment levels within 3 months of finishing the PUVA course. A comparison of the weal and flare responses on exposed and covered (control) skin using a calibrated dermographometer showed no significant change in skin reactivity, even in the patients who experienced symptomatic relief. While PUVA may temporarily reduce itching in some patients with symptomatic dermographism, its use cannot generally be justified for treating this type of physical urticaria.
一项针对14例重度症状性皮肤划痕症患者进行的为期4周的口服光化学疗法（PUVA）对照试验，使5例患者的瘙痒症状在临床上得到了有效减轻。在这5例患者中，有4例在完成PUVA疗程后的3个月内，瘙痒症状复发至治疗前水平。使用校准后的皮肤划痕仪对暴露皮肤和遮盖（对照）皮肤的风团和潮红反应进行比较，结果显示皮肤反应性无显著变化，即使是那些症状得到缓解的患者也是如此。虽然PUVA可能会暂时减轻一些症状性皮肤划痕症患者的瘙痒，但总体而言，其用于治疗此类物理性荨麻疹并不合理。
